Literature DB >> 12942703

Association between HLA-DR B1 and clinical features of adult onset Still's disease in Korea.

C I Joung1, H S Lee, S W Lee, C G Kim, Y H Song, J B Jun, W T Chung, J Y Choe, T G Kim, D H Yoo.   

Abstract

OBJECTIVE: To determine whether HLA-DR alleles are associated with the development and clinical features of Adult Onset Still's Disease (AOSD) in Korea.
METHODS: Forty-seven patients (41 women, 6 men, mean age at diagnosis 31.6 yr) meeting Yamaguchi's criteria for AOSD and 144 healthy controls were enrolled in this study. The patients with AOSD were subdivided into groups according to their chronicity: monocyclic systemic, polycyclic systemic, and chronic destructive type, and were furthermore classified as non-articular, oligoarticular or polyarticular types (having arthritis involving 5 or more joints) according to the extent of articular involvement. HLA-DRB1 genotypes were assessed by PCR-SSOP.
RESULTS: Patients with AOSD had more frequent DRB1*12 (p = 0.028, relative risk (RR) = 2.27, 95% confidence interval (CI): 1.08-4.80) and DRB1*15 (p = 0.013, RR = 2.16, 95% CI: 1.17-4.00). They had less frequent DRB1*04 (p = 0.006, RR = 0.35, 95% CI: 0.16-0.75) compared to controls. DRB1*14 (p = 0.011, RR = 3.80, 95% CI: 1.27-11.31) were associated with the monocyclic systemic type.
CONCLUSION: Korean AOSD patients had more frequent DRB1*12 and DRB1*15, and less frequent HLA-DRB1*04. The patients with the monocyclic systemic type had more frequent DRB1*14 alleles. This study suggests that Korean AOSD patients have distinct immunogenetic profiles, and that it would be valuable to assess the relationships between HLA-DRB1 genes and polymorphisms of proinflammatory cytokines in the pathogenesis of AOSD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942703

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  18 in total

Review 1.  Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.

Authors:  Paolo Sfriso; Sara Bindoli; Paola Galozzi
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

2.  Adult-Onset Still's Disease: A Case Report.

Authors:  Ong Ping Seung; Wahinuddin Sulaiman
Journal:  Oman Med J       Date:  2011-09

Review 3.  Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart.

Authors:  Yvan Jamilloux; Mathieu Gerfaud-Valentin; Fabio Martinon; Alexandre Belot; Thomas Henry; Pascal Sève
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

4.  Fever with persistent flagellate erythema in a primigravida: a rare presentation of adult-onset Still's disease.

Authors:  Riti Bhatia; Nidhi Kaeley; Ravi Kant; Ankith Basi
Journal:  BMJ Case Rep       Date:  2019-07-12

5.  Bibliometrics and Visual Analysis of Adult-onset Still Disease (1976-2020).

Authors:  Bowen Xu; Jian Wang; Xiaoying Meng; Binghao Bao
Journal:  Front Public Health       Date:  2022-06-15

Review 6.  Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.

Authors:  Apostolos Kontzias; Petros Efthimiou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  HLA and Disease Associations in Koreans.

Authors:  Stephen Ahn; Hee-Back Choi; Tai-Gyu Kim
Journal:  Immune Netw       Date:  2011-12-31       Impact factor: 6.303

Review 8.  Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still's Disease.

Authors:  Sheng Li; Siting Zheng; Shunli Tang; Yunlei Pan; Shan Zhang; Hong Fang; Jianjun Qiao
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 10.817

9.  Adult-Onset Still's Disease Associated with Thyroid Dysfunction: Case Report and Review of the Literature.

Authors:  Yingchun Hu; Han Wang; Juelin Deng
Journal:  Open Rheumatol J       Date:  2014-07-11

Review 10.  Adult-onset Still's disease: current challenges and future prospects.

Authors:  Mariam Siddiqui; Michael S Putman; Anisha B Dua
Journal:  Open Access Rheumatol       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.